Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2011; 17(44): 4858-4866
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858
Figure 1 Experimental design for development of colitis-associated dysplasia in a rat model and timeline for administration of erlotinib (10 mg/kg, ip).
TNBS: Trinitrobenzene sulfonic acid.
- Citation: Pagán B, Isidro AA, Cruz ML, Ren Y, Coppola D, Wu J, Appleyard CB. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol 2011; 17(44): 4858-4866
- URL: https://www.wjgnet.com/1007-9327/full/v17/i44/4858.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i44.4858